Screening | Inclusion | Switch (start sirolimus) | Switch + M1 ± 15 days | Follow-up during sirolimus treatment: every 2 months ±15 days | End of study | |
---|---|---|---|---|---|---|
J-30/J0* | J0 | Between month 4 and 8** | Between month 5 and 9** | Between month 7 and 11** | Month 12*** | |
Information | x | x | ||||
Inclusion/exclusion criteria | x | x | x | x | x | |
Medical history and demographics | x | x | ||||
Consent | x | |||||
Randomization | x | |||||
MRI | x1 | x | x | |||
Physical examination | x | x | x | x | x | |
General laboratory tests | x2 | x3 | x4 | x4 | ||
Coagulation markers, serum VEGF, tissue factor | x | x | x | x | ||
Serum level of sirolimus adjustments5 | x | x | ||||
Blood and skin samples for genetic analysis and collection (ancillary study) | x | |||||
Photographs | x | x | x | |||
Self-assessment for patients and proxy by visual analog scale | x | x | x | x | ||
Dermatological quality of life scale | x | x | x | x | x | |
Adverse events/serious adverse events6 | x | x | x |